News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

EDP Biotech Corporation Debuts CA1-18 Tumor Marker Assay For Early Stage Colorectal Cancer


10/16/2006 10:32:30 AM

KNOXVILLE, TN -- (MARKET WIRE) -- October 13, 2006 -- EDP Biotech Corporation (EDP), a diagnostics company focused on the development and sale of immunodiagnostic tests for humans, today announced the development of the CA1-18 Enzyme Immunoassay (EIA) to be used as an aid in the diagnosis and management of the colorectal cancer patient.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES